A new needle-free flu vaccine option is arriving in Australia this winter, potentially transforming how families protect their children from influenza. FluMist, a nasal spray vaccine, is now available for children aged 2 to 17 years across Australian states and territories, with some regions offering it free and others through private providers. The vaccine contains a weakened live form of the flu virus and is designed to trigger immune protection right where the flu enters the body: the nose and throat .

Why Are Parents Choosing the Nasal Vaccine Over Injections?

Fear of needles is a significant barrier to childhood vaccination. Less than one in four Australian children received the flu vaccine in 2025, a coverage rate that experts say could improve dramatically with a needle-free option . Recent studies from countries where both injectable and nasal vaccines are available show that parents strongly prefer the nasal option, particularly those who are hesitant about vaccination. The UK's experience is telling: after introducing a school-based nasal flu vaccine program in 2013, vaccination coverage jumped from very low rates to around half of all children receiving an annual flu vaccine .

The appeal is straightforward. A health professional simply sprays 0.1 milliliters of vaccine into each nostril. It is painless, takes seconds, and children tolerate it extremely well, even very young ones. This simplicity removes a major logistical hurdle in school-based vaccination programs and settings where administering injections is challenging.

How Does FluMist Work Differently Than Traditional Flu Shots?

Current flu vaccines used in Australia are all injected and contain specific components of the influenza virus that cannot replicate. FluMist takes a different approach. It contains a weakened "live" form of the flu strain, similar to vaccines for measles, mumps, rubella, chickenpox, and rotavirus .

The science behind FluMist is clever. Six of the eight genetic segments in the influenza virus are altered so the virus cannot replicate efficiently at normal body temperature. This means the virus only replicates in the nose, which is cooler than the rest of the body, rather than spreading deeper into the respiratory system. Unlike injected vaccines that trigger immune responses in the bloodstream, nasal vaccines stimulate protective immune responses on the mucosa, the surface lining of the upper respiratory tract where influenza viruses actually enter the body. In theory, this targeted approach should provide superior protection .

Is the Nasal Vaccine as Effective as the Injection?

Early studies from the late 1990s suggested FluMist provided excellent protection against influenza in children. However, real-world data from subsequent studies shows the nasal vaccine provides similar protection to injectable vaccines. Both reduce influenza infection by 40 to 60 percent .

The vaccine did face a credibility challenge in the United States during the mid-2010s, when the live attenuated nasal spray was found to be less effective than injected vaccines. This led to recommendations against its use from 2016 to 2018. However, changes were made to the process of selecting vaccine strains, and data from more recent seasons shows nasal spray vaccines are now just as effective as injected vaccines .

What Side Effects Should Parents Expect?

FluMist is safe, with mostly similar side effects to the injected influenza vaccine. Over half of children will experience a blocked or runny nose after receiving the spray, which makes biological sense given the vaccine is delivered to the nasal passages. Around one in ten children develop a fever or headache. These side effects are mild and temporary .

However, certain groups should not receive FluMist. Children who are severely immunosuppressed, or those who regularly take aspirin, should not use the nasal vaccine. If your child is mildly immunosuppressed, has severe asthma or another lung disease, speak with your general practitioner or specialist about whether FluMist is appropriate. Adolescents who are pregnant should also seek medical advice before receiving the vaccine .

How to Determine If Your Child Is Eligible for Free FluMist

• New South Wales and South Australia: Free for children aged 2 to 4 years; available privately for ages 5 to 17 at a cost of around $50 to $70
• Queensland: Free for children aged 2 to 5 years; available privately for ages 6 to 17
• Western Australia: Free for children aged 2 to 11 years; available privately for ages 12 to 17
• Australian Capital Territory, Northern Territory, Tasmania, and Victoria: Available on the private market for all children aged 2 to 17 years

Funding arrangements vary significantly across states and territories, so checking with your local health authority or pharmacy is essential to understand your eligibility and costs .

Why Does Increasing Flu Vaccination Coverage Matter for the Whole Community?

The benefits of higher vaccination coverage extend far beyond individual children. Evidence from the United Kingdom suggests that vaccinating school-aged children with the nasal flu vaccine reduced influenza presentations in all age groups, not just children. Vaccinated children are less likely to fall sick and miss school, and they are less likely to transmit the virus to vulnerable family members and community members .

"The main benefit of a nasal vaccine is improving coverage in an age group where fear of needles stops children getting vaccinated and in settings where needles are a logistical hurdle," explained Allen Cheng, Professor of Infectious Diseases at Monash University.

Allen Cheng, Professor of Infectious Diseases, Monash University

Reducing influenza community transmission is expected to result in fewer influenza cases overall, lower healthcare costs, and reduced pressure on hospitals and health providers. This is particularly important during winter months when respiratory illness peaks and healthcare systems are already strained .

FluMist has been safely used in the United States since 2003, Canada since 2010, and Europe since 2011. The United Kingdom has had a national childhood program using the nasal vaccine since 2013, providing years of real-world safety and effectiveness data . With FluMist now available in Australia, families have a new tool to protect their children from the flu without the needle barrier that has historically limited vaccination uptake in this age group.